Hypertension in PregnancyENHANCE-CVHNCT06773299

Enhancing Intergenerational Health in Nigeria: Peripartum as Critical Life Stage for Cardiovascular Health

A study testing PAT+HEALTH curriculum - Nigeria in people with Hypertension in Pregnancy and Hypertension, run by Washington University School of Medicine at 1 site in Nigeria.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 years and older, women only
Conditions the study is for: Hypertension in Pregnancy, Hypertension, Obesity and Overweight
What is being tested?: PAT+HEALTH curriculum - Nigeria
Type of treatment: Lifestyle or therapy programme
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 1,000 participants
Where: 1 siteNigeria
Study dates: 23 Jun 2025to Aug 2028
Phase: Interventional
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
Women only
No healthy volunteers
Adult, Older adult

Who may be able to join

•≥18 years of age,
Pregnant women under 14 weeks gestation,
Singleton gestation,
Body mass index > 30 kg/m2
Willing to participate in ENHANCE CVH for 2 years,
Planning to receive prenatal care and deliver at either one of the participating primary healthcare, centers or University of Abuja Teaching Hospital, and
Able to give informed consent for study participation, understanding she and her child will both be involved.

Who cannot join

Current enrollment in a weight loss program,
Inability to engage in a walking program,
Active substance abuse
Treatment with medications known to impact weight (e.g., corticosteroids, antipsychotics),
Plan to relocate within the next 2 years, or
Unwilling to provide informed consent.

Trial locations and contacts

1 site in 1 country.

Nigeria1 site

University of Abuja Teaching Hospital
Abuja

Other trials in Nigeria

About this study

Official title: ENhancing Intergenerational HeAlth in Nigeria: Peripartum as Critical Life StagE for CardioVascular Health

The purpose of the ENHANCE-CVH study is to promote intergenerational cardiovascular health (CVH) of women and children in Abuja and the surrounding Federal Capital Territory of Nigeria. The study team plans to achieve this through an adaptation of an existing evidence based intervention - Parents as Teachers (PAT) curriculum + Healthy Eating Active Living Taught at Home (HEALTH) - among pregnant women with obesity and their children in Nigeria. The aim of the study is to evaluate the effectiveness and implementation of community health educator-led delivery of the PAT+HEALTH intervention via home visits to answer the following main questions:

Will the women participating in the intervention have a greater change in weight from baseline to 18-month follow up compared to the women who do not?
Will the women and children in the intervention group display better CVH promoting lifestyle behaviors compared to those in the control group?

Participants in the study will complete baseline surveys and have clinical data, lab data, and body measurements captured. Participants will also have these procedures repeated at birth and every 6 months up to 24 months post-delivery. Once randomized to the intervention group, participants will complete 40 biweekly PAT+HEALTH curriculum delivery sessions, each lasting approximately 60-90 minutes.

Conditions: Hypertension in Pregnancy, Hypertension, Obesity and Overweight, Maternal Morbidity and Mortality, Maternal and Child Health Outcomes
Being tested: PAT+HEALTH curriculum - Nigeria
Keywords: Maternal Hypertension, Maternal and infant cardiovascular health, Hybrid Type 2 effectiveness-implementation, Obesity in pregnancy
Medical subject headings: Hypertension, Pregnancy-Induced, Hypertension, Obesity, Overweight, Pregnancy in Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

PAT+HEALTH curriculum - NigeriaBehavioural
This intervention is an adaption of the PAT Curriculum and the HEALTH intervention specifically tailored for the Nigerian context.

Study groups in NCT06773299
Study group	Role	What they receive
PAT+HEALTH Intervention	Experimental	Participants randomized to this arm will receive 40 biweekly PAT+HEALTH intervention delivery ante- and postnatally. These will primarily focus on promoting cardiovascular health for mother and child through lifestyle and behavioral modifications along with additional support and education for pregnancy and cardiovascular health. Receives: Behavioral: PAT+HEALTH curriculum - Nigeria
Control	No intervention	Participants randomized to the control group will not receive the PAT+HEALTH intervention and will only receive standard ante- and postnatal care.

What is being measured

The primary outcome is the main question the study is designed to answer.

Change in maternal body weight from baseline
Between group difference in change in maternal body weight f rom baseline to 18-month follow-up measured in kilograms.
Measured: Baseline to 18-month postnatal follow up

Secondary outcomes (17)

Change in cardiovascular health score
Between group difference in change in maternal cardiovascular health score (range from 0-100: Life's Essential 8) from baseline to 18-month postnatal follow-up.
Measured: Baseline to 18-month postnatal follow up
Change in cardiovascular health score - Tobacco Use/Exposure
Between group difference in change in Tobacco Use/exposure subscore (range from 0-100: Life's Essential 8) from baseline to 18-month postnatal follow-up.
Measured: Baseline to 18-month postnatal follow up
Change in cardiovascular health score - Diet
Between group difference in change in Diet subscore (range from 0-100: Life's Essential 8) from baseline to 18-month postnatal follow-up.
Measured: Baseline to 18-month postnatal follow up
Change in cardiovascular health score - Physical Activity
Between group difference in change in Physical Activity subscore (range from 0-100: Life's Essential 8) from baseline to 18-month postnatal follow-up.
Measured: Baseline to 18-month postnatal follow up
Change in cardiovascular health score - BMI
Between group difference in change in BMI subscore (range from 0-100: Life's Essential 8) from baseline to 18-month postnatal follow-up.
Measured: Baseline to 18-month postnatal follow up
Change in cardiovascular health score - Blood Pressure
Between group difference in change in blood pressure subscore (range from 0-100: Life's Essential 8) from baseline to 18-month postnatal follow-up.
Measured: Baseline to 18-month postnatal follow up
Change in cardiovascular health score - Cholesterol
Between group difference in change in cholesterol subscore (range from 0-100: Life's Essential 8) from baseline to 18-month postnatal follow-up.
Measured: Baseline to 18-month postnatal follow up
Change in cardiovascular health score - Blood Sugar
Between group difference in change in Blood Sugar subscore (range from 0-100: Life's Essential 8) from baseline to 18-month postnatal follow-up.
Measured: Baseline to 18-month postnatal follow up
Change in cardiovascular health score - Sleep
Between group difference in change in Sleep subscore (range from 0-100: Life's Essential 8) from baseline to 18-month postnatal follow-up.
Measured: Baseline to 18-month postnatal follow up
Change in Child CVH behaviors - Diet
Between group difference in child cardiovascular health behaviors as measured through parent-reported diet from birth to 18 months.
Measured: Birth to 18 months
Change in Child CVH behaviors - Physical Activity
Between group difference in child cardiovascular health behaviors as measured through parent-reported activity from birth to 18 months using the Movement Behavior Questionnaire - Child Open Version (MBQ-C)
Measured: Birth to 18 months
Change in Child CVH behaviors - Sleep
Between group difference in child cardiovascular health behaviors as measured through parent-reported sleep from birth to 18 months using the Brief Infant Sleep Questionnaire - Revised version (BISQ-R)
Measured: Birth to 18 months
Maternal Mortality
Between group difference in composite rate of maternal mortality from baseline to 18 months postnatal follow-up
Measured: Baseline to 18-month postnatal follow up
Maternal morbidity
Between group difference in composite rate of maternal morbidity (defined as occurrence of any serious adverse event) from baseline to 18 month postnatal follow-up.
Measured: Baseline to 18-month postnatal follow up
Stillbirth or spontaneous abortion
Between group difference in the composite rate of stillbirth or spontaneous abortion.
Measured: Measured at Birth
Neonatal, infant, and child mortality
Between group difference in the composite rate of neonatal, infant, or childhood mortality from birth to 18 months.
Measured: Birth to 18 months
Neonatal, infant, and child morbidity
Between group difference in the composite rate of neonatal, infant, or childhood morbidity as defined by occurrence of any serious adverse events from birth to 18 months.
Measured: Birth to 18 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

23 Jun 2025Aug 2028

First posted14 Jan 2025
Study start23 Jun 2025
Primary completionOct 2027 (estimated)
Study completionAug 2028 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (66)Papers the sponsor has linked to this study.
Other trials for Hypertension in PregnancyStudies of the same condition, open and under way.
More trials run by Washington University School of MedicineThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Triple blind
Who is masked: Participant, Care provider, Investigator
Enrolment: 1,000 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06773299
Sponsor's protocol ID: R01HL168771
Acronym: ENHANCE-CVH
Status last verified: Jul 2026
First submitted: 16 Dec 2024
Last updated: 24 Jul 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Yes: De-identified data will be made available after the conclusion of the study following the guidelines of BioData Catalyst. A codebook will be provided.

Publications

GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1160-1203. doi: 10.1016/S0140-6736(20)30977-6.
PubMed 33069325
Tukur J, Lavin T, Adanikin A, Abdussalam M, Bankole K, Ekott MI, Godwin A, Ibrahim HA, Ikechukwu O, Kadas SA, Nwokeji-Onwe L, Nzeribe E, Ogunkunle TO, Oyeneyin L, Tunau KA, Bello M, Aminu I, Ezekwe B, Aboyeji P, Adesina OA, Chama C, Etuk S, Galadanci H, Ikechebelu J, Oladapo OT; Maternal and Perinatal Database for Quality, Equity and Dignity Network. Quality and outcomes of maternal and perinatal care for 76,563 pregnancies reported in a nationwide network of Nigerian referral-level hospitals. EClinicalMedicine. 2022 Apr 28;47:101411. doi: 10.1016/j.eclinm.2022.101411. eCollection 2022 May.
PubMed 35518118
Abubakar I, Dalglish SL, Angell B, Sanuade O, Abimbola S, Adamu AL, Adetifa IMO, Colbourn T, Ogunlesi AO, Onwujekwe O, Owoaje ET, Okeke IN, Adeyemo A, Aliyu G, Aliyu MH, Aliyu SH, Ameh EA, Archibong B, Ezeh A, Gadanya MA, Ihekweazu C, Ihekweazu V, Iliyasu Z, Kwaku Chiroma A, Mabayoje DA, Nasir Sambo M, Obaro S, Yinka-Ogunleye A, Okonofua F, Oni T, Onyimadu O, Pate MA, Salako BL, Shuaib F, Tsiga-Ahmed F, Zanna FH. The Lancet Nigeria Commission: investing in health and the future of the nation. Lancet. 2022 Mar 19;399(10330):1155-1200. doi: 10.1016/S0140-6736(21)02488-0. Epub 2022 Mar 15. No abstract available.
PubMed 35303470
Parikh NI, Gonzalez JM, Anderson CAM, Judd SE, Rexrode KM, Hlatky MA, Gunderson EP, Stuart JJ, Vaidya D; American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and the Stroke Council. Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement From the American Heart Association. Circulation. 2021 May 4;143(18):e902-e916. doi: 10.1161/CIR.0000000000000961. Epub 2021 Mar 29.
PubMed 33779213
Nigeria Federal Ministry of Health (2019). National Multi-Sectoral Action Plan for the Prevention and Control of Non-Communicable Diseases; Federal Capital Territory, Nigeria.
Aifah A, Onakomaiya D, Iwelunmor J, Oladele D, Gbajabiamila T, Obiezu-Umeh C, Nwaozuru U, Musa AZ, Ezechi O, Ogedegbe G. Nurses' perceptions on implementing a task-shifting/sharing strategy for hypertension management in patients with HIV in Nigeria: a group concept mapping study. Implement Sci Commun. 2020 Jun 26;1:58. doi: 10.1186/s43058-020-00048-y. eCollection 2020.
PubMed 32885213
Wiltsey Stirman S, Baumann AA, Miller CJ. The FRAME: an expanded framework for reporting adaptations and modifications to evidence-based interventions. Implement Sci. 2019 Jun 6;14(1):58. doi: 10.1186/s13012-019-0898-y.
PubMed 31171014
Haire-Joshu D, Schwarz CD, Steger-May K, Lapka C, Schechtman K, Brownson RC, Tabak RG. A Randomized Trial of Weight Change in a National Home Visiting Program. Am J Prev Med. 2018 Mar;54(3):341-351. doi: 10.1016/j.amepre.2017.12.012.
PubMed 29455756
Haire-Joshu D, Cahill AG, Stein RI, Cade WT, Woolfolk CL, Moley K, Mathur A, Schwarz CD, Schechtman KB, Klein S. Randomized Controlled Trial of Home-Based Lifestyle Therapy on Postpartum Weight in Underserved Women with Overweight or Obesity. Obesity (Silver Spring). 2019 Apr;27(4):535-541. doi: 10.1002/oby.22413.
PubMed 30900408
Cahill AG, Haire-Joshu D, Cade WT, Stein RI, Woolfolk CL, Moley K, Mathur A, Schechtman K, Klein S. Weight Control Program and Gestational Weight Gain in Disadvantaged Women with Overweight or Obesity: A Randomized Clinical Trial. Obesity (Silver Spring). 2018 Mar;26(3):485-491. doi: 10.1002/oby.22070.
PubMed 29464907
Ojji DB, Baldridge AS, Orji IA, Shedul GL, Ojo TM, Ye J, Chopra A, Ale BM, Shedul G, Ugwuneji EN, Egenti NB, Aluka-Omitiran K, Okoli RCB, Eze H, Nwankwo A, Banigbe B, Tripathi P, Kandula NR, Hirschhorn LR, Huffman MD; Hypertension Treatment in Nigeria Program Investigators. Characteristics, treatment, and control of hypertension in public primary healthcare centers in Nigeria: baseline results from the Hypertension Treatment in Nigeria Program. J Hypertens. 2022 May 1;40(5):888-896. doi: 10.1097/HJH.0000000000003089. Epub 2022 Jan 15.
PubMed 35034080
Glasgow RE, Battaglia C, McCreight M, Ayele RA, Rabin BA. Making Implementation Science More Rapid: Use of the RE-AIM Framework for Mid-Course Adaptations Across Five Health Services Research Projects in the Veterans Health Administration. Front Public Health. 2020 May 27;8:194. doi: 10.3389/fpubh.2020.00194. eCollection 2020.
PubMed 32528921
Gemechu KS, Assefa N, Mengistie B. Prevalence of hypertensive disorders of pregnancy and pregnancy outcomes in Sub-Saharan Africa: A systematic review and meta-analysis. Womens Health (Lond). 2020 Jan-Dec;16:1745506520973105. doi: 10.1177/1745506520973105.
PubMed 33334273
Adeloye D, Ige-Elegbede JO, Ezejimofor M, Owolabi EO, Ezeigwe N, Omoyele C, Mpazanje RG, Dewan MT, Agogo E, Gadanya MA, Alemu W, Harhay MO, Auta A, Adebiyi AO. Estimating the prevalence of overweight and obesity in Nigeria in 2020: a systematic review and meta-analysis. Ann Med. 2021 Dec;53(1):495-507. doi: 10.1080/07853890.2021.1897665.
PubMed 33783281
Institute of Medicine (US) and National Research Council (US) Committee to Reexamine IOM Pregnancy Weight Guidelines; Rasmussen KM, Yaktine AL, editors. Weight Gain During Pregnancy: Reexamining the Guidelines. Washington (DC): National Academies Press (US); 2009. Available from http://www.ncbi.nlm.nih.gov/books/NBK32813/
PubMed 20669500

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
RecruitingPhase 3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Chronic Kidney Disease and Hypertension
Recruiting
Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial
End Stage Kidney Disease (ESKD), Hypertension (HTN)
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
RecruitingObservational study
Molecular Study of the Maternal-fetal Interface in Preeclampsia.
Preeclampsia

All Hypertension in Pregnancy trials

Study at a glance

From the registry record, last updated by the sponsor on 24 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: ENhancing Intergenerational HeAlth in Nigeria: Peripartum as Critical Life StagE for CardioVascular Health
ClinicalTrials.gov ID: NCT06773299
Acronym / sponsor ID: ENHANCE-CVH / R01HL168771
Conditions: Hypertension in Pregnancy, Hypertension, Obesity and Overweight, Maternal Morbidity and Mortality, Maternal and Child Health Outcomes
Keywords: Maternal Hypertension, Maternal and infant cardiovascular health, Hybrid Type 2 effectiveness-implementation, Obesity in pregnancy
Study type: Interventional
Recruitment status: Active, not recruiting
Enrolment: 1,000 participants (estimated)
Lead sponsor: Washington University School of MedicineUniversity, hospital or other
Collaborators: University of Abuja Teaching Hospital, New York University, Parents as Teachers
Study start: 23 Jun 2025 (actual)
Primary completion: Oct 2027 (estimated)
Study completion: Aug 2028 (estimated)
First posted: 14 Jan 2025 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Will the women participating in the intervention have a greater change in weight from baseline to 18-month follow up compared to the women who do not?
Will the women and children in the intervention group display better CVH promoting lifestyle behaviors compared to those in the control group?

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Triple blind (participant, care provider, investigator)
Number of arms: 2

Arm	Type	Receives
PAT+HEALTH Intervention	Experimental	Behavioral: PAT+HEALTH curriculum - NigeriaParticipants randomized to this arm will receive 40 biweekly PAT+HEALTH intervention delivery ante- and postnatally. These will primarily focus on promoting cardiovascular health for mother and child through lifestyle and behavioral modifications along with additional support and education for pregnancy and cardiovascular health.
Control	No intervention	–Participants randomized to the control group will not receive the PAT+HEALTH intervention and will only receive standard ante- and postnatal care.

Who may qualify

Ages: 18 years and older
Sex: Female only
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (7 listed)

•≥18 years of age,
Pregnant women under 14 weeks gestation,
Singleton gestation,
Body mass index > 30 kg/m2
Willing to participate in ENHANCE CVH for 2 years,

Key exclusion criteria (6 listed)

Current enrollment in a weight loss program,
Inability to engage in a walking program,
Active substance abuse
Treatment with medications known to impact weight (e.g., corticosteroids, antipsychotics),
Plan to relocate within the next 2 years, or

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
PAT+HEALTH curriculum - NigeriaThis intervention is an adaption of the PAT Curriculum and the HEALTH intervention specifically tailored for the Nigerian context.	Behavioural	PAT+HEALTH Intervention

Primary outcome

Change in maternal body weight from baseline
Time frame: Baseline to 18-month postnatal follow up
Between group difference in change in maternal body weight f rom baseline to 18-month follow-up measured in kilograms.

17 secondary outcomes

Change in cardiovascular health score
Time frame: Baseline to 18-month postnatal follow up
Change in cardiovascular health score - Tobacco Use/Exposure
Time frame: Baseline to 18-month postnatal follow up
Change in cardiovascular health score - Diet
Time frame: Baseline to 18-month postnatal follow up
Change in cardiovascular health score - Physical Activity
Time frame: Baseline to 18-month postnatal follow up
Change in cardiovascular health score - BMI
Time frame: Baseline to 18-month postnatal follow up
Change in cardiovascular health score - Blood Pressure
Time frame: Baseline to 18-month postnatal follow up
Change in cardiovascular health score - Cholesterol
Time frame: Baseline to 18-month postnatal follow up
Change in cardiovascular health score - Blood Sugar
Time frame: Baseline to 18-month postnatal follow up
Change in cardiovascular health score - Sleep
Time frame: Baseline to 18-month postnatal follow up
Change in Child CVH behaviors - Diet
Time frame: Birth to 18 months
Change in Child CVH behaviors - Physical Activity
Time frame: Birth to 18 months
Change in Child CVH behaviors - Sleep
Time frame: Birth to 18 months
Maternal Mortality
Time frame: Baseline to 18-month postnatal follow up
Maternal morbidity
Time frame: Baseline to 18-month postnatal follow up
Stillbirth or spontaneous abortion
Time frame: Measured at Birth
Neonatal, infant, and child mortality
Time frame: Birth to 18 months
Neonatal, infant, and child morbidity
Time frame: Birth to 18 months

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 24 Jul 2026.
Background: PubMed 33069325GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1160-1203. doi: 10.1016/S0140-6736(20)30977-6.
Background: PubMed 35518118Tukur J, Lavin T, Adanikin A, Abdussalam M, Bankole K, Ekott MI, Godwin A, Ibrahim HA, Ikechukwu O, Kadas SA, Nwokeji-Onwe L, Nzeribe E, Ogunkunle TO, Oyeneyin L, Tunau KA, Bello M, Aminu I, Ezekwe B, Aboyeji P, Adesina OA, Chama C, Etuk S, Galadanci H, Ikechebelu J, Oladapo OT; Maternal and Perinatal Database for Quality, Equity and Dignity Network. Quality and outcomes of maternal and perinatal care for 76,563 pregnancies reported in a nationwide network of Nigerian referral-level hospitals. EClinicalMedicine. 2022 Apr 28;47:101411. doi: 10.1016/j.eclinm.2022.101411. eCollection 2022 May.
Background: PubMed 35303470Abubakar I, Dalglish SL, Angell B, Sanuade O, Abimbola S, Adamu AL, Adetifa IMO, Colbourn T, Ogunlesi AO, Onwujekwe O, Owoaje ET, Okeke IN, Adeyemo A, Aliyu G, Aliyu MH, Aliyu SH, Ameh EA, Archibong B, Ezeh A, Gadanya MA, Ihekweazu C, Ihekweazu V, Iliyasu Z, Kwaku Chiroma A, Mabayoje DA, Nasir Sambo M, Obaro S, Yinka-Ogunleye A, Okonofua F, Oni T, Onyimadu O, Pate MA, Salako BL, Shuaib F, Tsiga-Ahmed F, Zanna FH. The Lancet Nigeria Commission: investing in health and the future of the nation. Lancet. 2022 Mar 19;399(10330):1155-1200. doi: 10.1016/S0140-6736(21)02488-0. Epub 2022 Mar 15. No abstract available.
Background: PubMed 33779213Parikh NI, Gonzalez JM, Anderson CAM, Judd SE, Rexrode KM, Hlatky MA, Gunderson EP, Stuart JJ, Vaidya D; American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and the Stroke Council. Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement From the American Heart Association. Circulation. 2021 May 4;143(18):e902-e916. doi: 10.1161/CIR.0000000000000961. Epub 2021 Mar 29.
BackgroundNigeria Federal Ministry of Health (2019). National Multi-Sectoral Action Plan for the Prevention and Control of Non-Communicable Diseases; Federal Capital Territory, Nigeria.
Background: PubMed 32885213Aifah A, Onakomaiya D, Iwelunmor J, Oladele D, Gbajabiamila T, Obiezu-Umeh C, Nwaozuru U, Musa AZ, Ezechi O, Ogedegbe G. Nurses' perceptions on implementing a task-shifting/sharing strategy for hypertension management in patients with HIV in Nigeria: a group concept mapping study. Implement Sci Commun. 2020 Jun 26;1:58. doi: 10.1186/s43058-020-00048-y. eCollection 2020.
Background: PubMed 31171014Wiltsey Stirman S, Baumann AA, Miller CJ. The FRAME: an expanded framework for reporting adaptations and modifications to evidence-based interventions. Implement Sci. 2019 Jun 6;14(1):58. doi: 10.1186/s13012-019-0898-y.
Background: PubMed 29455756Haire-Joshu D, Schwarz CD, Steger-May K, Lapka C, Schechtman K, Brownson RC, Tabak RG. A Randomized Trial of Weight Change in a National Home Visiting Program. Am J Prev Med. 2018 Mar;54(3):341-351. doi: 10.1016/j.amepre.2017.12.012.
Background: PubMed 30900408Haire-Joshu D, Cahill AG, Stein RI, Cade WT, Woolfolk CL, Moley K, Mathur A, Schwarz CD, Schechtman KB, Klein S. Randomized Controlled Trial of Home-Based Lifestyle Therapy on Postpartum Weight in Underserved Women with Overweight or Obesity. Obesity (Silver Spring). 2019 Apr;27(4):535-541. doi: 10.1002/oby.22413.
Background: PubMed 29464907Cahill AG, Haire-Joshu D, Cade WT, Stein RI, Woolfolk CL, Moley K, Mathur A, Schechtman K, Klein S. Weight Control Program and Gestational Weight Gain in Disadvantaged Women with Overweight or Obesity: A Randomized Clinical Trial. Obesity (Silver Spring). 2018 Mar;26(3):485-491. doi: 10.1002/oby.22070.
Background: PubMed 35034080Ojji DB, Baldridge AS, Orji IA, Shedul GL, Ojo TM, Ye J, Chopra A, Ale BM, Shedul G, Ugwuneji EN, Egenti NB, Aluka-Omitiran K, Okoli RCB, Eze H, Nwankwo A, Banigbe B, Tripathi P, Kandula NR, Hirschhorn LR, Huffman MD; Hypertension Treatment in Nigeria Program Investigators. Characteristics, treatment, and control of hypertension in public primary healthcare centers in Nigeria: baseline results from the Hypertension Treatment in Nigeria Program. J Hypertens. 2022 May 1;40(5):888-896. doi: 10.1097/HJH.0000000000003089. Epub 2022 Jan 15.
Background: PubMed 32528921Glasgow RE, Battaglia C, McCreight M, Ayele RA, Rabin BA. Making Implementation Science More Rapid: Use of the RE-AIM Framework for Mid-Course Adaptations Across Five Health Services Research Projects in the Veterans Health Administration. Front Public Health. 2020 May 27;8:194. doi: 10.3389/fpubh.2020.00194. eCollection 2020.
Related InfoLink provided by the sponsor.
Individual participant dataSharing planned: Yes. De-identified data will be made available after the conclusion of the study following the guidelines of BioData Catalyst. A codebook will be provided.

Related trials for Hypertension in Pregnancy

Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
RecruitingPhase 3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Chronic Kidney Disease and Hypertension
Recruiting
Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial
End Stage Kidney Disease (ESKD), Hypertension (HTN)
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
RecruitingObservational study
Molecular Study of the Maternal-fetal Interface in Preeclampsia.
Preeclampsia

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Dike B Ojji, MD principal investigator

University of Abuja Teaching Hospital

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing PAT+HEALTH curriculum - Nigeria in people with Hypertension in Pregnancy and Hypertension, run by Washington University School of Medicine at 1 site in Nigeria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 24 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Nigeria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in maternal body weight from baseline (time frame: Baseline to 18-month postnatal follow up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06773299, which also lists 66 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2026.